TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06152705

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Typical treatments involve 30 to 45 minutes daily sessions delivered over 4 to 6 weeks. Recent technical advances allowed the development of theta burst stimulation (TBS), a novel rTMS paradigm that reduces daily sessions to 3 to 4 minutes while maintaining the same clinical efficacy. This study will specifically be administering intermittent TBS (iTBS), which is a novel refinement of conventional rTMS and consists of bursts of 3 stimulations at 50 Hz at theta frequency (5 Hz).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Typical treatments involve 30 to 45 minutes daily sessions delivered over 4 to 6 weeks. Recent technical advances allowed the development of theta burst stimulation (TBS), a novel rTMS paradigm that reduces daily sessions to 3 to 4 minutes while maintaining the same clinical efficacy. This study will specifically be administering intermittent TBS (iTBS), which is a novel refinement of conventional rTMS and consists of bursts of 3 stimulations at 50 Hz at theta frequency (5 Hz).
Study: NCT05424250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: occasional aversive imagination
Description: During six of the 27 exposure trials, participants in the experimental group are asked to imagine their most feared outcome towards spiders as vividly as possible while completing the specific trial.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure
Description: • All participants complete an exposure training session (approx. 75 min) with seven exposure steps, which are repeated between one and five times (e.g. Step 4: directing the spider with a pen by touching its legs at least five times per repetition; this step must be repeated five times before continuing to the next step). One repetition per step is considered one trial, therefore each participant aims to complete 27 exposure trials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: • All participants complete an exposure training session (approx. 75 min) with seven exposure steps, which are repeated between one and five times (e.g. Step 4: directing the spider with a pen by touching its legs at least five times per repetition; this step must be repeated five times before continuing to the next step). One repetition per step is considered one trial, therefore each participant aims to complete 27 exposure trials.
Study: NCT05567016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active case detection using molecular testing (ACDm)
Description: In the ACDm arm, children will receive ACD using RDT and qPCR 3x yearly with treatment using artemether-lumefantrine (AL) if RDT or qPCR positive. With fevers, participants will receive standard PCD using RDT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive case detection using molecular testing (PCDm)
Description: With fevers, participants will receive PCDm, in which qPCR will be done in RDT negatives with treatment using AL if positive.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (standard of care)
Description: With fevers, participants will receive standard PCD using RDT with treatment using AL if positive.
Study: NCT05373277

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin
Description: 10 mg tablet, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 10 mg tablet, single dose
Study: NCT06030050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal-assisted intervention
Description: The AAI is designed to promote patient comfort, uplift mood, and provide an opportunity for socialization. The nature of the dog interaction involves several different components, including but not limited to: petting the dog, talking to the dog, watching the dog do tricks, conversing with the dog handler, and being prompted to discuss any fond memories/stories of their own personal experiences with human-animal interactions. Therapy dogs are trained and certified animals who are leashed at all times and under direct care of their dog handler, NOT companion animals, personal pets, nor emotional support animals.
Study: NCT05986786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patients will receive 1 IVT injection of AVT06 PFS depending on their chorioretinal vascular disease schedule
Description: Patient will receive AVT06 (proposed aflibercept biosimilar) PFS injection
Study: NCT06748456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cluster meeting
Description: A two-hour meeting facilitated by either the GPs cluster coordinator, another GP from the cluster or a facilitator outside the cluster chosen by the cluster itself with specific slides about PSA in general, guidelines, expert videos, data from the clinics, cases, and group discussions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand-out material 1
Description: Hand-outs of the main take-home messages to facilitate further discussion in their respective GP offices

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand-out material 2
Description: Hand-outs to be used by GP and patients to facilitate communication about the relevance of taking a PSA-test
Study: NCT06750380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored mat exercise program
Description: The Group A will receive TENS plus moist hot pack and follow the Tailored mat exercise program for 10 weeks, two times per week, in 45-min sessions under supervision of trained physical therapist. The choice of exercises will be made based on the suggested exercises of Wood for the treatment of back pain, while the easiest versions of each exercise would be selected in order for the program to be adapted to older adults. Patient's outcomes will be measured at baseline and after 10 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: McKenzie exercises
Description: The Group B will receive McKenzie exercises plus moist hot pack and TENS in the region of lumbar spine for 10 minutes and Mckenzie exercises of seven to ten repetitions for 45 min/session two times per week for ten weeks. Patient's outcomes will be measured at baseline and after 10 weeks.
Study: NCT06751264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peritoneal combined with intrauterine water isolation
Description: On the basis of the conventional peritoneal water isolation group, the improved technology group added additional intrauterine water isolation, and continued to inject ice saline to separate the endometrium on both sides.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peritoneal water isolation
Description: Transabdominal injection of saline into the abdominal cavity to achieve complete separation of the uterus from the surrounding organs and structures
Study: NCT03645460

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Direct intravenous injection of ivlv-ADA lentiviral vector
Description: Injection of ivlv-ADA lentiviral vector at \~1x10\^9 per kg body weight
Study: NCT04514835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin+Capecitabine+Sintilimab
Description: The first stage:concurrent chemoradiotherapy，cisplatin，25-30mg/m2 ivgtt d1;capecitabine,800mg/m2, bid d1-5，qw，5weeks;concurrent radiotherapy,1.8-2Gy/d，5d/W，50-50.4Gy.~second stage:Sintilimab, 200mg,q3w, a total of 3 times，Each infusion lasted for 30-60 min until disease progression or intolerable toxicity, with a maximum duration of no more than 12 months.
Study: NCT05976243

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treated groups and arms

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treated groups and arms

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treated groups and arms
Study: NCT05761509

Intervention type: DRUG
Intervention: Doravirine
Description: The study treatments will used during 28 days according to the routine care of each investigator center.
Study: NCT04663802

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Default order set
Description: With the default order set strategy, some mechanical ventilation order settings will be pre-populated to be consistent with LPV, including the mode and tidal volume, automatically calculated as 6 milliliters per kilogram of predicted body weight (cc/kg PBW; as determined by each patient's height and gender). The physician will have the option to opt out of any of the specified LPV settings and select other values.
Study: NCT06163404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of Spirair Nasal Device using the Spirair delivery system.
Description: The Spirair implant is designed to acutely correct cartilaginous septal deviation and maintain the cartilage in a corrected position for a duration sufficient to allow for cartilaginous remodeling.
Study: NCT04309682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: crestal sinus approach technique
Description: a Full thickness flap will be elevated at the edentulous site with two vertical releasing incision and then the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral sinus approach
Description: a full-thickness flap will be elevated at the edentulous site with two vertical releasing incisions extending to the vestibule for better reflection and exposure to the lateral wall of the sinus. The lateral antrostomy will be prepared in the lateral sinus wall using rotary bur no. 8 to provide adequate access to remove the thin to thick cortical bone and to expose the thin sinus membrane. The membrane will be elevated across the sinus floor and up the medial wall and this elevation must extend anteriorly-posteriorly to provide the exposed sinus floor. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place
Study: NCT04697823

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: use of hyaluronan-enriched transfer medium
Description: In the study group, an embryo transfer will be performed in hyaluronan-enriched transfer medium
Study: NCT05984290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthokeratology lens
Description: Each subject will wear the study lenses in both eyes overnight for approximately 3 months.
Study: NCT06421649

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy
Description: All patients will be offered radical adjuvant proton beam therapy to a dose of 60-66 Gray (Gy) in 30-33 fractions delivered Monday to Friday over 6-6.5 weeks.
Study: NCT04875169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Core Treatment Active Experimental: SHR0302 Dose#1
Description: Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Core Treatment Active Experimental: SHR0302 Dose#2
Description: Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Core Treatment Placebo Comparator: Placebo
Description: Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extension Treatment Active Experimental: SHR0302 Dose#1
Description: Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extension Treatment Active Experimental: SHR0302 Dose#2
Description: Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
Study: NCT05617950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: salicylic acid
Description: Salicylic acid is applied once daily by the patients (or parents) for a maximum of 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: Cryotherapy is delivered by a technician up to a maximum of four treatments 3 weeks apart.
Study: NCT03301805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLEX 404
Description: BLEX 404 Oral Liquid is administered twice daily during the Gemcitabine monotherapy period. The dose of Gemcitabine 1,000 mg/m2 IV fusion at Day 1, 8, 15 of every cycle~* 28 days a cycle.
Study: NCT05185323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding usual known aids and osteopathic treatment
Description: Breastfeeding usual known aids and osteopathic treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding usual known aids
Description: Breastfeeding usual known aids
Study: NCT06248567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273
Description: Oral
Study: NCT05192967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pandemic preparedness via video
Description: A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a video demonstration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pandemic preparedness via video
Description: A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a video demonstration.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pandemic preparedness via classical method
Description: A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a classical method.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pandemic preparedness via classical method
Description: A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a classical method.
Study: NCT05253846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: chemotherapy treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: chemotherapy treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lederfolin
Description: treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: chemotherapy treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: RT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME
Description: surgery
Study: NCT04663802

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Default order set
Description: With the default order set strategy, some mechanical ventilation order settings will be pre-populated to be consistent with LPV, including the mode and tidal volume, automatically calculated as 6 milliliters per kilogram of predicted body weight (cc/kg PBW; as determined by each patient's height and gender). The physician will have the option to opt out of any of the specified LPV settings and select other values.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician-targeted accountable justification
Description: When a physician enters a mechanical ventilation order for a tidal volume that is greater than 6 cc/kg PBW, an alert will appear requiring the physician to enter a reason for choosing a setting inconsistent with LPV. Clinicians will be instructed to provide a reason for deviation from LPV settings and that their response will be maintained in the medical record. The physician will not be able to sign the mechanical ventilation order set until after a response is entered.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician-targeted accountable justification
Description: When a physician enters a mechanical ventilation order for a tidal volume that is greater than 6 cc/kg PBW, an alert will appear requiring the physician to enter a reason for choosing a setting inconsistent with LPV. Clinicians will be instructed to provide a reason for deviation from LPV settings and that their response will be maintained in the medical record. The physician will not be able to sign the mechanical ventilation order set until after a response is entered.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory therapist (RT)-targeted accountable justification
Description: If an RT enters a tidal volume in a flowsheet documentation field value greater than 6 cc/kg PBW, an alert will appear requiring them to enter a reason for entering a setting inconsistent with LPV. Clinicians will be instructed to provide a reason for deviation from LPV settings and that their response will be maintained in the medical record. The RT will not be able to save the documentation in the EHR until after a response is entered.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory therapist (RT)-targeted accountable justification
Description: If an RT enters a tidal volume in a flowsheet documentation field value greater than 6 cc/kg PBW, an alert will appear requiring them to enter a reason for entering a setting inconsistent with LPV. Clinicians will be instructed to provide a reason for deviation from LPV settings and that their response will be maintained in the medical record. The RT will not be able to save the documentation in the EHR until after a response is entered.
Study: NCT04598529

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A2 milk
Description: a variety of cow's milk that contains only A2 beta-casein (and therefore lacks of A1 beta-casein).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional milk
Description: cow's milk with a mixture of A1 and A2 beta-casein.
Study: NCT06383351

Intervention type: OTHER
Intervention: Questionnaire
Description: Two sets of questionnaires will be administered to patients:~* Questionnaire about their perception of peri-implant disease (Brief Illness Perception Questionnaire; 9 questions, answers will be registered on a scale of 0 to 10);~* Oral Health Impact Profile 14 (OHIP-14) questionnaire.
Study: NCT05825235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: 6 months of treatment with add-on Pramipexole
Study: NCT06326528

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: Dapagliflozin 10 mg or Empagliflozin 25mg
Study: NCT04927325

Intervention type: OTHER
Group type: OTHER
Intervention: Set of Photos
Description: A standardized set of photos will be taken with a tablet camera, SLR, thermal camera.

Intervention type: OTHER
Group type: OTHER
Intervention: Set of Photos
Description: A standardized set of photos will be taken with a tablet camera, SLR, thermal camera.
Study: NCT05245851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opportunistic screening for low BMD
Description: Software will analyze x-rays of the chest, thoracic spine, lumbar spine, pelvis, knee or hand/wrist acquired for any reason, and notify the radiologist at time of acquisition if low BMD is detected. The report to the radiologist includes the following statements:~* This x-ray was opportunistically analyzed by RhoTM, an investigational device under ITA \[investigational testing authorization\] from Health Canada, to screen for low bone mineral density (low BMD).~* This information should be used by a trained healthcare provider in conjunction with a patient's clinical fracture risk to determine if formal BMD screening with DXA is appropriate.~The radiologist can choose to include this as an incidental finding in their report to the referring physician.
Study: NCT06166758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: Educational video regarding the benefits, risks, and limitations of genetic testing for hereditary cancer risk.
Study: NCT04916613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide 300 mg
Description: 600 mg po, b.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po, b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Description: Use according to local standard of care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Androgen deprivation therapy
Description: Use according to local standard of care
Study: NCT06494098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasoalveolar Molding
Description: presurgical orthopedics

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasoalveolar Molding
Description: presurgical orthopedics

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Addition silicone impression
Description: diagnostic impression for maxillary arch and nose

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Addition silicone impression
Description: diagnostic impression for maxillary arch and nose
Study: NCT06368687

Intervention type: OTHER
Group type: OTHER
Intervention: Anorexia nervosa plus autism
Description: In the inpatient care the treatment model takes into account the patient's perception disorders, meaning e.g. an adapted mealtime situation where the patient can eat separately or wear hearing protection if necessary. The patients have an adapted meal plan regarding difficulties with specific textures or foods. To meet their need for continuity, they have the same contact persons throughout the entire period of care. The healthcare staff receive training in working with the specific subgroup and have regular exchanges of experience regarding the patient group, 15 minutes every or every two weeks.
Study: NCT06408233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Performance Coaching
Description: Performance coaching will consist of working with clinic staff to understand and guide current quality measurement practices as well as improving quality measurement and implementing new measures and management practices.
Study: NCT05523713

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Peripheral venous blood samples
Description: 10 ml in a sodium heparin tube and 5 ml in an EDTA tube
Study: NCT04724369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-MFBG
Description: Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent